(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 17.44% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.1%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.68%.
Pulmonx's revenue in 2025 is $83,789,000.On average, 2 Wall Street analysts forecast LUNG's revenue for 2025 to be $3,861,247,651, with the lowest LUNG revenue forecast at $3,860,252,740, and the highest LUNG revenue forecast at $3,862,242,561. On average, 2 Wall Street analysts forecast LUNG's revenue for 2026 to be $4,560,470,750, with the lowest LUNG revenue forecast at $4,476,699,286, and the highest LUNG revenue forecast at $4,644,242,214.
In 2027, LUNG is forecast to generate $5,375,103,467 in revenue, with the lowest revenue forecast at $5,154,830,283 and the highest revenue forecast at $5,595,376,652.